Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Financial Report: Novartis | Contract Pharma

What are you searching for?

Sign in
Financial News

Financial Report: Novartis

Growth in the quarter driven by Cosentyx and Entresto

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Novartis
4Q Revenues: $12.9 billion (+5%)
4Q Earnings: $2.0 billion (+111%)
FY Revenues: $49.1 billion (+1%)
FY Earnings: $7.7 billion (+15%)
Comments: Innovative medicines sales were $8.8 billion in the quarter, up 6%. Growth in the quarter was driven by Cosentyx (up 57% to $615 million) and Entresto (up 172% to $185 million), partly offset by the negative impact of generic competition and pricing. Gleevec/Glivec sales were down 41% to $448 million impacted by generic competition. Tasigna sales were $485 million in the quarter, up 6%. Sandostatin sales were $421 million, up 3%. Afinitor/Votubia sales were $407 million, up 4%. Exjade sales were up 19% to $281 million. Tafinlar + Mekinist sales were up 38% to $246 million. Ultibro sales were $120 million, up 33%. Xolair sales were $247 million, up 14%. Gilenya sales were $825 million, up 2%. Earnings growth in the quarter was driven by income from associated companies, which amounted to $416 million compared to $156 million in 4Q16. The increase was mainly due to higher income recognized from the company’s investment in GSK Consumer Healthcare Holdings Ltd.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters